0001209191-23-016401.txt : 20230306
0001209191-23-016401.hdr.sgml : 20230306
20230306171206
ACCESSION NUMBER: 0001209191-23-016401
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230302
FILED AS OF DATE: 20230306
DATE AS OF CHANGE: 20230306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nolan Mangini Siobhan
CENTRAL INDEX KEY: 0001679464
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38853
FILM NUMBER: 23709883
MAIL ADDRESS:
STREET 1: C/O NMG BIOPHARMACEUTICALS, INC.
STREET 2: 333 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NGM BIOPHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001426332
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-243-5555
MAIL ADDRESS:
STREET 1: 333 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-02
0
0001426332
NGM BIOPHARMACEUTICALS INC
NGM
0001679464
Nolan Mangini Siobhan
C/O NGM BIOPHARMACEUTICALS, INC.
333 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
President and CFO
Common Stock
2023-03-02
4
A
0
76000
0.00
A
76000
D
Stock Option (Right to Buy)
4.36
2023-03-02
4
A
0
228000
0.00
A
2033-03-01
Common Stock
228000
228000
D
Stock Option (Right to Buy)
4.36
2023-03-02
4
A
0
200000
0.00
A
2033-03-01
Common Stock
200000
200000
D
Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.
/s/ Valerie Pierce, Attorney-in-fact
2023-03-06